============================================================
QUALITATIVE ERROR ANALYSIS REPORT
Generated on: 2025-08-21 13:59:25
Model: Phi-3.5 2.7B
Dataset: HEP
============================================================

1. BASIC PERFORMANCE METRICS:
   Accuracy: 0.924
   Precision: 0.869
   Sensitivity: 1.000
   F1-Score: 0.930
   Total samples: 2542
   TP: 1271, TN: 1079, FP: 192, FN: 0

2. SMILES COMPLEXITY ANALYSIS:
   False Positives: 192 cases
     Avg combined SMILES length: 116.1 ± 82.7
   True Positives: 1271 cases
     Avg combined SMILES length: 152.3 ± 71.6
   True Negatives: 1079 cases
     Avg combined SMILES length: 112.0 ± 54.9

3. GENE TARGET COMPLEXITY ANALYSIS:
   False Positives: 192 cases
     Avg combined gene targets: 8.3 ± 14.6
   True Positives: 1271 cases
     Avg combined gene targets: 6.9 ± 8.1
   True Negatives: 1079 cases
     Avg combined gene targets: 5.5 ± 15.5

4. ORGANISM PATTERN ANALYSIS:
   Top false positives organism pairs:
     Humans - Humans: 137 cases
     Escherichia coli (strain K12) - Humans: 5 cases
     Humans - Escherichia coli (strain K12): 5 cases
     Humans - Hepatitis C Virus: 4 cases
     Enteric bacteria and other eubacteria - Humans: 3 cases

5. MOST PROBLEMATIC DRUGS:
   Cyanamide: 1.000 error rate
     (1/1 errors: 1 FP, 0 FN)
   (5R,6S,8S)-8-[3-(AMINOMETHYL)PHENYL]-6-HYDROXY-5-ISOPROPYL-3-OXO-1-PHENYL-2,7-DIOXA-4-AZA-6-PHOSPHANONAN-9-OIC ACID 6-OXIDE: 1.000 error rate
     (1/1 errors: 1 FP, 0 FN)
   Bioallethrin: 1.000 error rate
     (1/1 errors: 1 FP, 0 FN)
   Mazindol: 1.000 error rate
     (1/1 errors: 1 FP, 0 FN)
   GW-3965: 1.000 error rate
     (1/1 errors: 1 FP, 0 FN)
   Bromamphenicol: 1.000 error rate
     (1/1 errors: 1 FP, 0 FN)
   BMS184394: 1.000 error rate
     (1/1 errors: 1 FP, 0 FN)
   Clocortolone: 1.000 error rate
     (1/1 errors: 1 FP, 0 FN)
   Copper: 1.000 error rate
     (1/1 errors: 1 FP, 0 FN)
   Ibalizumab: 1.000 error rate
     (1/1 errors: 1 FP, 0 FN)

6. SPECIFIC ERROR EXAMPLES:
   False Positives (predicted interaction, but no real interaction):
     1. Eptifibatide + Tixagevimab
        Organisms: Humans - SARS-CoV-2
        Gene targets: 3 - 1
     2. Cyanamide + Ixekizumab
        Organisms: Humans - Humans
        Gene targets: 2 - 1
     3. (5R,6S,8S)-8-[3-(AMINOMETHYL)PHENYL]-6-HYDROXY-5-ISOPROPYL-3-OXO-1-PHENYL-2,7-DIOXA-4-AZA-6-PHOSPHANONAN-9-OIC ACID 6-OXIDE + Phenprocoumon
        Organisms: Humans - Humans
        Gene targets: 1 - 1
     4. Bioallethrin + Tolazoline
        Organisms: Humans - Humans
        Gene targets: 49 - 6
     5. Mazindol + Myxothiazol
        Organisms: Humans - Humans
        Gene targets: 4 - 1

7. SUMMARY INSIGHTS:
   - Model tends to over-predict interactions (more false positives than false negatives)
   - High sensitivity but lower precision - good at catching interactions but with some false alarms

Report generation completed successfully.
============================================================
